Update on proposal to move to one funded brand of lamotrigine (Logem)
26 October 2018
PHARMAC would like to thank everyone who provided feedback on a proposal to move to one funded brand of lamotrigine (Logem).
After reviewing the feedback, we have determined that we require additional time to consider the issues raised before a decision can be made on the proposal.
This means that a decision will not be made in time to implement the proposal from 1 December 2018, as proposed in the consultation. At this stage we do not have a firm timeframe for when a decision will be made.
If you have any questions about this update, please contact email@example.com.
Last updated: 26 October 2018